Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial von Naismith, Robert T, Cohen, Jeffrey A, Bar-Or, Amit, Comi, Giancarlo, Selmaj, Krzysztof W, Hartung, Hans-Peter, Sheffield, James K, Krakovich, Anthony, Tatosian, Daniel, Cheng, Chun-Yen, Reardon, Jennifer, Khaychuk, Vadim, Riolo, Jon V, Silva, Diego, Cree, Bruce AC

Volltext

Safety Patterns over Time with Ozanimod During an Open-label Extension Trial in Patients with Relapsing Multiple Sclerosis (P10-6.012) von Selmaj, Krzysztof, Ziemssen, Tjalf, Comi, Giancarlo, Hartung, Hans-Peter, Reardon, Jennifer, Thorpe, Andrew, Riolo, Jon, Cheng, Chun-Yen, Sheffield, James, Krakovich, Anthony, Vermersch, Patrick, Cree, Bruce

Volltext

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis von Dubinsky, Marla C, Charles, Lorna, Selmaj, Krzysztof W, Comi, Giancarlo, Krakovich, Anthony, Rosen, Melissa, van der Woude, C Janneke, Mahadevan, Uma

Volltext

Safety of the Concurrent Administration of Serotonergic Antidepressants and Ozanimod in Patients With Relapsing Multiple Sclerosis (P7-3.013) von Naismith, Robert T., Cohen, Jeffrey A., Bar-Or, Amit, Comi, Giancarlo, Selmaj, Krzysztof W., Hartung, Hans-Peter, Sheffield, James K., Krakovich, Anthony, Cheng, Chun-Yen, Reardon, Jennifer, Riolo, Jon V., Silva, Diego, Cree, Bruce A. C.

Volltext